Cathepsin G-induced release of PAI-1 in the culture medium of endothelial cells

A new thrombogenic role for polymorphonuclear leukocytes?

Giuseppe Pintucci, Licia Iacoviello, Maria Paola Castelli, Concetta Amore, Virgilio Evangelista, Chiara Cerletti, Maria Benedetta Donati

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Activated polymorphonuclear leukocytes (PMNs) may affect the integrity of blood vessels by endothelial cell injury. We investigated the effects of cathepsin G purified from human neutrophils on the fibrinolytic potential of cultured human umbilical vein endothelial cells (HUVECs). Cathepsin G (5 and 10 μg/ml) induced marked intercellular gap formation after 1 hour of treatment, whereas 1 μg/ml did not, even after 6 hours incubation. In contrast, plasminogen activator inhibitor-1 (PAI-1) antigen levels, measured by a double antibody enzyme-linked immunosorbent assay, were significantly increased in culture media (CM) on cathepsin G (1 μg/ml) treatment after 15 minutes (5.1 ± 1.2 ng/ml vs 2.6 ± 0.6 ng/ml for controls, p <0.01) and 6 hours of incubation (69.6 ± 17.5 ng/ml vs 40.0 ± 9.0 ng/ml for controls, p <0.01). Likewise, PAI activity, measured by reverse fibrin autography, increased on cell treatment with cathepsin G. Preincubation of cathepsin G with eglin C (10 μg/ml) almost completely abolished the increase in both PAI antigen and activity levels induced by cathepsin G. Cycloheximide, a protein synthesis inhibitor, did not block cathepsin G-induced PAI-1 release. PAI-1 mRNA levels were not affected by HUVEC treatment with cathepsin G (1 μg/ml for 15 minutes), even after 24 hours. In the extracellular matrix (ECM) PAI-1 antigen levels decreased to 77% and 40% of controls, respectively, after 15 minutes and 6 hours of cathepsin G (1 μg/ml) treatment. Reverse fibrin autography also demonstrated a dose-dependent reduction of PAI activity in the ECM on 6 hours of cell treatment with 1 or 5 μg/ml cathepsin G. Moreover, ECM prepared from confluent HUVECs released PAI-1 in supernatants on 1 μg/ml cathepsin G incubation in a cell-free system. Tissue-type plasminogen activator (t-PA) activity was strongly depressed on cathepsin G treatment, both in CM from HUVECs or in a cell-free system. Finally, PAI-1 was also released from cathepsin G-stimulated platelets in a dose-dependent manner. In summary, our results support a potentially thrombogenic role of cathepsin G, which could impair the fibrinolytic potential of the endothelium. These data give a new insight into the mechanisms by which activated PMNs may promote thrombus formation. On the other hand, the decrease of PAI-1 in ECM could favor penetration and migration of inflammatory or tumor cells through the subendothelial layers.

Original languageEnglish
Pages (from-to)69-79
Number of pages11
JournalThe Journal of Laboratory and Clinical Medicine
Volume122
Issue number1
Publication statusPublished - 1993

Fingerprint

Cathepsin G
Plasminogen Activator Inhibitor 1
Culture Media
Neutrophils
Endothelial Cells
Human Umbilical Vein Endothelial Cells
Extracellular Matrix
Cell-Free System
Fibrin
Antigens
Therapeutics
Protein Synthesis Inhibitors
Tissue Plasminogen Activator
Cycloheximide

ASJC Scopus subject areas

  • Medicine(all)
  • Pathology and Forensic Medicine

Cite this

Cathepsin G-induced release of PAI-1 in the culture medium of endothelial cells : A new thrombogenic role for polymorphonuclear leukocytes? / Pintucci, Giuseppe; Iacoviello, Licia; Castelli, Maria Paola; Amore, Concetta; Evangelista, Virgilio; Cerletti, Chiara; Donati, Maria Benedetta.

In: The Journal of Laboratory and Clinical Medicine, Vol. 122, No. 1, 1993, p. 69-79.

Research output: Contribution to journalArticle

@article{242507424de94e2f81e41fb26f7dad76,
title = "Cathepsin G-induced release of PAI-1 in the culture medium of endothelial cells: A new thrombogenic role for polymorphonuclear leukocytes?",
abstract = "Activated polymorphonuclear leukocytes (PMNs) may affect the integrity of blood vessels by endothelial cell injury. We investigated the effects of cathepsin G purified from human neutrophils on the fibrinolytic potential of cultured human umbilical vein endothelial cells (HUVECs). Cathepsin G (5 and 10 μg/ml) induced marked intercellular gap formation after 1 hour of treatment, whereas 1 μg/ml did not, even after 6 hours incubation. In contrast, plasminogen activator inhibitor-1 (PAI-1) antigen levels, measured by a double antibody enzyme-linked immunosorbent assay, were significantly increased in culture media (CM) on cathepsin G (1 μg/ml) treatment after 15 minutes (5.1 ± 1.2 ng/ml vs 2.6 ± 0.6 ng/ml for controls, p <0.01) and 6 hours of incubation (69.6 ± 17.5 ng/ml vs 40.0 ± 9.0 ng/ml for controls, p <0.01). Likewise, PAI activity, measured by reverse fibrin autography, increased on cell treatment with cathepsin G. Preincubation of cathepsin G with eglin C (10 μg/ml) almost completely abolished the increase in both PAI antigen and activity levels induced by cathepsin G. Cycloheximide, a protein synthesis inhibitor, did not block cathepsin G-induced PAI-1 release. PAI-1 mRNA levels were not affected by HUVEC treatment with cathepsin G (1 μg/ml for 15 minutes), even after 24 hours. In the extracellular matrix (ECM) PAI-1 antigen levels decreased to 77{\%} and 40{\%} of controls, respectively, after 15 minutes and 6 hours of cathepsin G (1 μg/ml) treatment. Reverse fibrin autography also demonstrated a dose-dependent reduction of PAI activity in the ECM on 6 hours of cell treatment with 1 or 5 μg/ml cathepsin G. Moreover, ECM prepared from confluent HUVECs released PAI-1 in supernatants on 1 μg/ml cathepsin G incubation in a cell-free system. Tissue-type plasminogen activator (t-PA) activity was strongly depressed on cathepsin G treatment, both in CM from HUVECs or in a cell-free system. Finally, PAI-1 was also released from cathepsin G-stimulated platelets in a dose-dependent manner. In summary, our results support a potentially thrombogenic role of cathepsin G, which could impair the fibrinolytic potential of the endothelium. These data give a new insight into the mechanisms by which activated PMNs may promote thrombus formation. On the other hand, the decrease of PAI-1 in ECM could favor penetration and migration of inflammatory or tumor cells through the subendothelial layers.",
author = "Giuseppe Pintucci and Licia Iacoviello and Castelli, {Maria Paola} and Concetta Amore and Virgilio Evangelista and Chiara Cerletti and Donati, {Maria Benedetta}",
year = "1993",
language = "English",
volume = "122",
pages = "69--79",
journal = "Journal of Laboratory and Clinical Medicine",
issn = "0022-2143",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Cathepsin G-induced release of PAI-1 in the culture medium of endothelial cells

T2 - A new thrombogenic role for polymorphonuclear leukocytes?

AU - Pintucci, Giuseppe

AU - Iacoviello, Licia

AU - Castelli, Maria Paola

AU - Amore, Concetta

AU - Evangelista, Virgilio

AU - Cerletti, Chiara

AU - Donati, Maria Benedetta

PY - 1993

Y1 - 1993

N2 - Activated polymorphonuclear leukocytes (PMNs) may affect the integrity of blood vessels by endothelial cell injury. We investigated the effects of cathepsin G purified from human neutrophils on the fibrinolytic potential of cultured human umbilical vein endothelial cells (HUVECs). Cathepsin G (5 and 10 μg/ml) induced marked intercellular gap formation after 1 hour of treatment, whereas 1 μg/ml did not, even after 6 hours incubation. In contrast, plasminogen activator inhibitor-1 (PAI-1) antigen levels, measured by a double antibody enzyme-linked immunosorbent assay, were significantly increased in culture media (CM) on cathepsin G (1 μg/ml) treatment after 15 minutes (5.1 ± 1.2 ng/ml vs 2.6 ± 0.6 ng/ml for controls, p <0.01) and 6 hours of incubation (69.6 ± 17.5 ng/ml vs 40.0 ± 9.0 ng/ml for controls, p <0.01). Likewise, PAI activity, measured by reverse fibrin autography, increased on cell treatment with cathepsin G. Preincubation of cathepsin G with eglin C (10 μg/ml) almost completely abolished the increase in both PAI antigen and activity levels induced by cathepsin G. Cycloheximide, a protein synthesis inhibitor, did not block cathepsin G-induced PAI-1 release. PAI-1 mRNA levels were not affected by HUVEC treatment with cathepsin G (1 μg/ml for 15 minutes), even after 24 hours. In the extracellular matrix (ECM) PAI-1 antigen levels decreased to 77% and 40% of controls, respectively, after 15 minutes and 6 hours of cathepsin G (1 μg/ml) treatment. Reverse fibrin autography also demonstrated a dose-dependent reduction of PAI activity in the ECM on 6 hours of cell treatment with 1 or 5 μg/ml cathepsin G. Moreover, ECM prepared from confluent HUVECs released PAI-1 in supernatants on 1 μg/ml cathepsin G incubation in a cell-free system. Tissue-type plasminogen activator (t-PA) activity was strongly depressed on cathepsin G treatment, both in CM from HUVECs or in a cell-free system. Finally, PAI-1 was also released from cathepsin G-stimulated platelets in a dose-dependent manner. In summary, our results support a potentially thrombogenic role of cathepsin G, which could impair the fibrinolytic potential of the endothelium. These data give a new insight into the mechanisms by which activated PMNs may promote thrombus formation. On the other hand, the decrease of PAI-1 in ECM could favor penetration and migration of inflammatory or tumor cells through the subendothelial layers.

AB - Activated polymorphonuclear leukocytes (PMNs) may affect the integrity of blood vessels by endothelial cell injury. We investigated the effects of cathepsin G purified from human neutrophils on the fibrinolytic potential of cultured human umbilical vein endothelial cells (HUVECs). Cathepsin G (5 and 10 μg/ml) induced marked intercellular gap formation after 1 hour of treatment, whereas 1 μg/ml did not, even after 6 hours incubation. In contrast, plasminogen activator inhibitor-1 (PAI-1) antigen levels, measured by a double antibody enzyme-linked immunosorbent assay, were significantly increased in culture media (CM) on cathepsin G (1 μg/ml) treatment after 15 minutes (5.1 ± 1.2 ng/ml vs 2.6 ± 0.6 ng/ml for controls, p <0.01) and 6 hours of incubation (69.6 ± 17.5 ng/ml vs 40.0 ± 9.0 ng/ml for controls, p <0.01). Likewise, PAI activity, measured by reverse fibrin autography, increased on cell treatment with cathepsin G. Preincubation of cathepsin G with eglin C (10 μg/ml) almost completely abolished the increase in both PAI antigen and activity levels induced by cathepsin G. Cycloheximide, a protein synthesis inhibitor, did not block cathepsin G-induced PAI-1 release. PAI-1 mRNA levels were not affected by HUVEC treatment with cathepsin G (1 μg/ml for 15 minutes), even after 24 hours. In the extracellular matrix (ECM) PAI-1 antigen levels decreased to 77% and 40% of controls, respectively, after 15 minutes and 6 hours of cathepsin G (1 μg/ml) treatment. Reverse fibrin autography also demonstrated a dose-dependent reduction of PAI activity in the ECM on 6 hours of cell treatment with 1 or 5 μg/ml cathepsin G. Moreover, ECM prepared from confluent HUVECs released PAI-1 in supernatants on 1 μg/ml cathepsin G incubation in a cell-free system. Tissue-type plasminogen activator (t-PA) activity was strongly depressed on cathepsin G treatment, both in CM from HUVECs or in a cell-free system. Finally, PAI-1 was also released from cathepsin G-stimulated platelets in a dose-dependent manner. In summary, our results support a potentially thrombogenic role of cathepsin G, which could impair the fibrinolytic potential of the endothelium. These data give a new insight into the mechanisms by which activated PMNs may promote thrombus formation. On the other hand, the decrease of PAI-1 in ECM could favor penetration and migration of inflammatory or tumor cells through the subendothelial layers.

UR - http://www.scopus.com/inward/record.url?scp=0027197393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027197393&partnerID=8YFLogxK

M3 - Article

VL - 122

SP - 69

EP - 79

JO - Journal of Laboratory and Clinical Medicine

JF - Journal of Laboratory and Clinical Medicine

SN - 0022-2143

IS - 1

ER -